Business Context and Reporting Period
This Form 8-K is a current report filed by NeuroBo Pharmaceuticals, Inc. (not Metavia Inc.) on March 18, 2022. The registrant is a Delaware corporation with its principal executive offices in Boston, Massachusetts. The report addresses a regulatory notice received from the Nasdaq Stock Market regarding the continued listing of the Company's common stock (Trading Symbol: NRBO).
Key Financial Metrics
The filing does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial metric disclosed is the stock price performance: the closing bid price for the Company's common stock was below $1.00 for 30 consecutive trading days prior to March 18, 2022.
Material Changes
The material event reported is the receipt of a Notice of Delisting or Failure to Satisfy a Continued Listing Rule from Nasdaq. The Company is currently non-compliant with Nasdaq Marketplace Rule 5550(a)(2) due to the sustained low stock price. This represents a significant change in the Company's listing status, triggering a compliance period.
Guidance, Outlook, and Risks
- Compliance Period: The Company has 180 calendar days (until September 14, 2022) to regain compliance by maintaining a closing bid price of at least $1.00 per share for 10 consecutive trading days.
- Contingency Plan: If the Company fails to regain compliance by the initial deadline, it may be eligible for an additional 180-day period if it meets other listing standards (e.g., market value of publicly held shares) and notifies Nasdaq of its intent to cure the deficiency, potentially via a reverse stock split.
- Risks: There is no assurance the Company will regain compliance, secure an extension, or avoid delisting. If delisting occurs, the Company may appeal to a Nasdaq hearings panel.
- Management Commentary: Management intends to actively monitor the stock price and consider available options to resolve the deficiency.
Investor Verification Checklist
- Verify the current trading price of NRBO to assess proximity to the $1.00 compliance threshold.
- Monitor subsequent filings for announcements regarding a reverse stock split or other capital structure changes.
- Check for any updates on the Company's market value of publicly held shares to determine eligibility for a second compliance period.
- Review the Company's cash position in other filings (e.g., 10-K or 10-Q) to understand its ability to fund operations if delisting impacts liquidity.